OBJECTIVE: To assess the long-term ototoxicity effect of platinum chemotherapy in a series of pediatric patients. DESIGN: A prospective cohort study. METHODS: Patients who received platinum chemotherapy were identified through review of the pharmacy records from 2000 to 2005. Audiograms pre- and post-treatment with cisplatin were noted. The patients were brought back long after treatment for a repeat audiogram and a questionnaire to assess the impact of ototoxicity on their quality of life. RESULTS: Forty-nine patients received platinum chemotherapy. Patients' exclusion: two had no pre-chemo audiograms, one had retinoblastoma with congenital hearing loss, three were lost to follow up, five deceased, and seven refused participation. The total number of patients included was 31 with long-term follow up total of 21 patients. The follow up period ranged from 1.5 to 6.6 years (median of 3.4 years). Fourty-two percent (13/31) of the patients suffered from otoxicity (3 mild, 3 moderate, 7 severe-profound). Thirty-three (7/21) of audiograms worsened on long-term follow up. Questionnaire revealed 70% subjective hearing loss with 40% requiring hearing aids. CONCLUSION: Ototoxicity after platinum chemotherapy can present or worsen years after completion of therapy. Therefore, we recommend long-term follow up.
OBJECTIVE: To assess the long-term ototoxicity effect of platinum chemotherapy in a series of pediatric patients. DESIGN: A prospective cohort study. METHODS:Patients who received platinum chemotherapy were identified through review of the pharmacy records from 2000 to 2005. Audiograms pre- and post-treatment with cisplatin were noted. The patients were brought back long after treatment for a repeat audiogram and a questionnaire to assess the impact of ototoxicity on their quality of life. RESULTS: Forty-nine patients received platinum chemotherapy. Patients' exclusion: two had no pre-chemo audiograms, one had retinoblastoma with congenital hearing loss, three were lost to follow up, five deceased, and seven refused participation. The total number of patients included was 31 with long-term follow up total of 21 patients. The follow up period ranged from 1.5 to 6.6 years (median of 3.4 years). Fourty-two percent (13/31) of the patients suffered from otoxicity (3 mild, 3 moderate, 7 severe-profound). Thirty-three (7/21) of audiograms worsened on long-term follow up. Questionnaire revealed 70% subjective hearing loss with 40% requiring hearing aids. CONCLUSION:Ototoxicity after platinum chemotherapy can present or worsen years after completion of therapy. Therefore, we recommend long-term follow up.
Authors: Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Johnnie K Bass; Kristin R Knight; Torunn I Yock; Kay W Chang; Douglas Cipkala; Satkiran S Grewal Journal: Pediatr Blood Cancer Date: 2016-02-29 Impact factor: 3.167
Authors: Allyson M Womack; Andrea Hayes-Jordan; Rajarshi Pratihar; Denise A Barringer; James H Hall; Paul W Gidley; Jan S Lewin Journal: Ear Hear Date: 2014 Nov-Dec Impact factor: 3.570
Authors: Ayotunde J Fasunla; Nadia Harbeck; Barbara Schmalfeld; Sabina Berktold; Christina Böhner; Walter Hundt; Petra Wolf; Silke Steinbach Journal: Breast Care (Basel) Date: 2013-08 Impact factor: 2.860
Authors: Miranda L Camet; Susan S Hayashi; Belinda C Sinks; Jennifer Henry; Katie Gettinger; Ashley Hite; Juliann Kiefer; Caroline Mohrmann; Taryn Sandheinrich; Feng Gao; Robert J Hayashi Journal: Pediatr Blood Cancer Date: 2018-01-30 Impact factor: 3.167
Authors: A Dimitrios Colevas; Ruth R Lira; Electra A Colevas; Philip W Lavori; Cato Chan; David B Shultz; Kay W Chang Journal: Head Neck Date: 2014-07-11 Impact factor: 3.147
Authors: Eva Clemens; Marry M van den Heuvel-Eibrink; Renée L Mulder; Leontien C M Kremer; Melissa M Hudson; Roderick Skinner; Louis S Constine; Johnnie K Bass; Claudia E Kuehni; Thorsten Langer; Elvira C van Dalen; Edith Bardi; Nicolas-Xavier Bonne; Penelope R Brock; Beth Brooks; Bruce Carleton; Eric Caron; Kay W Chang; Karen Johnston; Kristin Knight; Paul C Nathan; Etan Orgel; Pinki K Prasad; Jan Rottenberg; Katrin Scheinemann; Andrica C H de Vries; Thomas Walwyn; Annette Weiss; Antoinette Am Zehnhoff-Dinnesen; Richard J Cohn; Wendy Landier Journal: Lancet Oncol Date: 2019-01 Impact factor: 54.433
Authors: Miranda L Camet; Anne Spence; Susan S Hayashi; Ningying Wu; Jennifer Henry; Kara Sauerburger; Robert J Hayashi Journal: Front Oncol Date: 2021-06-28 Impact factor: 6.244